

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 9, 2005

THE COOPER COMPANIES, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

1-8597
(Commission File Number)

94-2657368
(IRS Employer
Identification No.)

6140 Stoneridge Mall Road, Suite 590, Pleasanton, California 94588
(Address of principal executive offices)

(925) 460-3600
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. Regulation FD Disclosure.

On December 9, 2005, The Cooper Companies, Inc. (Cooper) issued a press release publicly announcing that CooperVision, Inc., the contact lens unit of Cooper, expects that its new silicone hydrogel contact lens will be available in the United States in the second half of 2006 and European introduction of the lens is currently underway. A copy of this press release is furnished as Exhibit 99.1 to this Current Report and is incorporated by reference herein, and this press release shall not be deemed "filed" under the Securities Exchange Act of 1934, as amended.

Internet addresses in this release are for information purposes only and are not intended to be hyperlinks to other Cooper information.

ITEM 9.01. Financial Statements and Exhibits.

(c) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated December 9, 2005 of The Cooper Companies, Inc.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE COOPER COMPANIES, INC.

By /s/ Rodney E. Folden
Rodney E. Folden
Corporate Controller
(Principal Accounting Officer)

Dated: December 9, 2005

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>	<u>Sequentially Numbered Page</u>
99.1	Press Release dated December 9, 2005 of The Cooper Companies, Inc.	



NEWS RELEASE

21062 Bake Parkway
 Lake Forest, CA 92630
 888-822-2660
 Fax: 949-597-0662

CONTACT:

Norris Battin
 The Cooper Companies, Inc.
 ir@coopercompanies.com

FOR IMMEDIATE RELEASE

COOPER COMPANIES' UNIT ANNOUNCES NEW SILICONE HYDROGEL CONTACT LENS

LAKE FOREST, Calif., December 9, 2005 – CooperVision, Inc., the contact lens unit of the Cooper Companies, Inc. (NYSE: COO), said today at the annual meeting of the American Academy of Optometry (AAO) that it expects that its new *Biofinity* silicone hydrogel contact lens will be available in the United States in the second half of 2006. European introduction of the lens is currently underway.

With high oxygen transmission, high water content and low modulus, *Biofinity* offers exceptional comfort in the eye. Modulus is a measure of contact lens rigidity. Low modulus enhances patient wearing comfort.

Manufactured from a unique naturally wettable material, comfilcon A, *Biofinity* does not require a wetting agent in its formulation or a surface treatment step during its manufacture. Comfilcon A provides a high level of oxygen transmissibility, and its relatively high water content ensures that the modulus remains low giving a soft, flexible, naturally wettable, comfortable lens.

Biofinity also offers a patented molded rounded lens edge which contributes to wearing comfort and enhanced ocular health. Its aspheric front surface design improves visual acuity, and the back surface is designed to distribute pressure forces across the surface providing additional comfort to the lens wearer.

Clinical research, some of which was presented at this year's AAO meeting, demonstrates that *Biofinity* offers excellent comfort and physiological performance in both daily and overnight wear. The lens has been extremely well accepted in these clinical trials. Many lens wearers expressed a preference for *Biofinity* over currently available silicone hydrogel lens materials and designs.

Forward-Looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including a statement about the introduction of a new product. To identify these statements look for words like "believes," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Discussions of strategy, plans or intentions often contain forward-looking statements. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. These include the risk that the release of the new product will be delayed or not occur at all. Events, among others, that could cause future actions of the Company to differ materially from those described in forward-looking statements include, among others, major changes in business conditions, a major disruption in the operations of our manufacturing or distribution facilities, new competitors or technologies, worldwide regulatory issues, including product recalls and the effect of healthcare reform legislation, the adverse effects on patients, practitioners and product distribution of natural disasters, and other events described in our Securities and Exchange Commission filings, including the "Business" section in Cooper's Annual Report on Form 10-K for the

fiscal year ended October 31, 2004. We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.

Corporate Information

The Cooper Companies, Inc. manufactures and markets specialty healthcare products through its CooperVision and CooperSurgical units. Corporate offices are in Lake Forest and Pleasanton, Calif. The World Wide Web address is www.coopercos.com. A toll free interactive telephone system at 1-800-334-1986 provides stock quotes, recent press releases and financial data.

CooperVision manufactures and markets contact lenses and ophthalmic surgery products. Headquartered in Lake Forest, Calif., it manufactures in Albuquerque, N.M., Juana Diaz, Puerto Rico, Norfolk, Va., Rochester, N.Y., Adelaide, Australia, Hamble and Hampshire England, Ligny-en-Barrios, France, Madrid, Spain and Toronto. Its Web address is www.coopervision.com.

CooperSurgical manufactures and markets diagnostic products, surgical instruments and accessories to the women's healthcare market. With headquarters and manufacturing facilities in Trumbull, Conn., it also manufactures in Pasadena, Calif., North Normandy, Ill., Fort Atkinson, Wis., Montreal and Berlin. Its Web address is www.coopersurgical.com.

Biofinity[™] is a trademark of The Cooper Companies, Inc. and its subsidiaries or affiliates and is italicized in this news release.